Submitting changes to labelling and patient information leaflets

AI Summary

This MHRA guidance outlines the obligations for marketing authorization holders regarding updates to product labeling and patient information leaflets. When changes are made that do not involve modifications to the Summary of Product Characteristics (SPC), companies must still notify the MHRA. The regulatory framework requires that all such adjustments be officially submitted to ensure continued compliance with safety and clarity standards for healthcare products in the UK. The main issues addressed include the necessity of maintaining accurate patient-facing information even when the core clinical data remains unchanged. Marketing authorization holders are tasked with choosing between two submission pathways: a full assessment or a notification scheme. A full assessment is typically required for more substantial layout or design changes, whereas the notification scheme allows for a streamlined process for minor updates. Required actions for companies include reviewing all proposed labeling changes against existing guidelines and submitting the relevant documentation through the MHRA portal. Failure to report these changes can lead to non-compliance with UK pharmaceutical regulations. This guidance ensures that patients receive the most current information regarding their medications through a structured regulatory oversight process, maintaining the integrity of medical information provided to the public.